RedHill Biopharma Ltd. (NASDAQ:RDHL)‘s stock had its “buy” rating restated by investment analysts at FBR & Co in a research report issued on Thursday.

Separately, Zacks Investment Research lowered shares of RedHill Biopharma from a “hold” rating to a “sell” rating in a research note on Friday, July 29th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $26.20.

Analyst Recommendations for RedHill Biopharma (NASDAQ:RDHL)

RedHill Biopharma (NASDAQ:RDHL) traded up 3.61% on Thursday, hitting $13.79. 75,218 shares of the stock were exchanged. The company has a 50-day moving average of $14.80 and a 200-day moving average of $12.74. RedHill Biopharma has a 12 month low of $8.10 and a 12 month high of $16.54. The stock’s market cap is $175.60 million.

RedHill Biopharma (NASDAQ:RDHL) last posted its quarterly earnings data on Wednesday, July 27th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.52. On average, equities analysts predict that RedHill Biopharma will post ($2.06) EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of RDHL. Van ECK Associates Corp boosted its position in shares of RedHill Biopharma by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock valued at $105,000 after buying an additional 138 shares during the period. Oppenheimer & Co. Inc. bought a new position in RedHill Biopharma during the second quarter valued at $142,000. Royal Bank of Canada boosted its position in RedHill Biopharma by 0.9% in the first quarter. Royal Bank of Canada now owns 21,167 shares of the company’s stock valued at $259,000 after buying an additional 191 shares during the last quarter. Finally, Ingalls & Snyder LLC bought a new position in RedHill Biopharma during the second quarter valued at $451,000. 15.30% of the stock is owned by institutional investors and hedge funds.

About RedHill Biopharma

5 Day Chart for NASDAQ:RDHL

Receive News & Stock Ratings for RedHill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd. and related stocks with our FREE daily email newsletter.